FEB 27, 2019 08:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Prepare for success: GMP cell banks as part of a staged, standardized, platform-style cell production process

Speakers
  • CEO and Co-Founder of Pluristyx Inc.
    Biography
      Ben Fryer is the CEO and co-founder of Pluristyx Inc. providing GMP pre-expanded pluripotent stem cells, contract development services, and consultancy for groups and company developing cell and tissue therapies. Ben has almost 25 years of experience as a leader and scientist in large pharma, academia, and start-up companies developing combination products and cell therapies. He has worked to generate GMP/ clinical grade pluripotent stem cells from early banking through large scale expansion using scalable, closed-loop, suspension reactor processes to manufacture cell therapy treatments for diabetes and heart disease.

      Ben is an inventor on multiple issued patents and patent applications for BetaLogics/Janssen/ J&J, including a bioreactor based, stem cell suspension expansion and differentiation process and a product currently marketed by Thermo-Fisher(TM) as Nunclon-Vita.

      Ben earned his BA from Colorado College, his PhD from UPENN, and studied as a post-doctoral fellow in the Howard Hughes Laboratory of M. Celeste Simon at the University of Pennsylvania investigating the role of Hypoxia Inducible Factor in cancer and stem cell development.

    Abstract:
    DATE:  February 27, 2019
    TIME:  8:00am PST
     
    Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture replacement organs and cellular therapies. Many groups have shown therapeutic proof-of-concept of PSC-derived cells or tissues in relevant animal models, but PSCs are still more of a promise than a reality because of manufacturing challenges.  The task of manufacturing a sufficient number of cells under Good Manufacturing Practices (GMP) to enable clinical trials and eventual commercialization is a substantial hurdle. Furthermore, all allogeneic therapies, including those derived from PSCs, must meet strict regulatory requirements. One such requirement is the need for extensive, costly characterization and safety testing of the parental cell line and the subsequent master and working cell banks (MCB/WCB). The time and expense required to complete this testing necessitates the MCB be of sufficient quality and size to meet not only the requirements of a Phase 1 regulatory filing (IND), but also for the lifetime of the product through late stage trials and commercialization. This presentation will focus on the “how and why” of integrating high quality ancillary raw materials into cell therapy product development and manufacturing workflow, beginning with the starting cell source and MCB.  Generation of a high-quality MCB is especially crucial for PSC-derived therapies because the first and most critically important step in product manufacturing is procurement of GMP-compliant starting material that meet regulatory requirements. Consequently, using high-quality raw materials from suppliers experienced in supporting cell therapy development and GMP manufacturing increase the probability of success and reduce the risk of costly surprises that could spell clinical or financial failure for a promising cell therapy product.  
     
    Learning Objectives:
    • Understand how and why cell banking is used for cell therapy manufacturing
    • Understand how and why to incorporate quality reagents and raw materials early in the development process
     
    Watch our related webinars here:
     
     

    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    Loading Comments...
    Show Resources
    Event Countdown
    • 0 Days
    • 0 Hours
    • 0 Minutes
    • 0 Seconds